Article

Bausch + Lomb expands I/A handpieces line

The latest innovation to Bausch + Lomb's Storz ophthalmic instruments, the silicone CapsuleGuard IA line, has expanded from two to ten single-use instruments and provides cataract surgeons with a wider range of options for both incisions and techniques for irrigation and aspiration.

Chicago-The latest innovation to Bausch + Lomb’s Storz ophthalmic instruments, the silicone CapsuleGuard IA line, has expanded from two to ten single-use instruments and provides cataract surgeons with a wider range of options for both incisions and techniques for irrigation/aspiration (I/A).

The line now offers surgeons the smaller, MICS 1.8 incision option, in addition to the standard 2.2 to 2.8 incision ranges. The single-use, silicone instruments also have three new tip designs, allowing surgeons a wider array of techniques for I/A. The line is compatible with Bausch + Lomb’s Stellaris PC Vision Enhancement System, as well as other ophthalmic surgical platforms.

“Our customers and the patients they serve are at the center of every development we bring to market,” said Cal Roberts, MD, executive vice president and chief medical officer, Bausch + Lomb. “This new offering in our signature Storz line was based on direct feedback from the industry’s surgeons who told us they wanted more choices to better treat their cataract surgery patients.”

The Storz CapsuleGuard IA line of instruments was launched in 2010 and features a smooth silicone exterior surface without exposed metal; a flexible tip for use in the removal of peripheral and subincisional cortical material and capsule polishing; and a soft aspiration port that allows for capsule vacuuming for lens epithelial cell removal. The product line is ideal for lens positioning and post-implant viscoelastic removal.

The Storz CapsuleGuard IA line is available in the United States, Australia, Canada, Europe, Hong Kong, India, and Malaysia.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.